64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing Metastatic Castrate Resistant Prostate Cancer (SECuRE)
64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing Metastatic Castrate Resistant Prostate Cancer (SECuRE)
Recruiting · NCT04868604 · Registry updated 2026-05-06Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| 64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing Metastatic Castrate Resistant Prostate Cancer (SECuRE) | Genital Diseases, Male Urogenital Diseases, Neoplasms by Site, Prostatic Neoplasms, Castration-Resistant, Urogenital Diseases, Urogenital Neoplasms, male reproductive organ cancer, male reproductive system disorder, neoplasm, prostate cancer, prostate disorder | Recruiting | Phase 1 / Phase 2 | 2026-05-06 | NCT04868604 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Clarity Pharmaceuticals Ltd | 3 |
7 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| BAMF Health | Grand Rapids | United States | 15 |
| East Jefferson General Hospital | River Ridge | United States | 1 |
| Mayo Clinic | Rochester | United States | 664 |
| Stanford Cancer Institute | Stanford | United States | 19 |
| Washington University School of Medicine at Barnes-Jewish Hospital | St Louis | United States | 1 |
| Weill Cornell Medicine at New York-Presbyterian | New York | United States | 1 |
| XCancer | Omaha | United States | 7 |